Rapidly progressive glomerulonephritis medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 5: Line 5:
==Overview==  
==Overview==  
==Medical therapy==
==Medical therapy==
Treatment of RPGN must be very aggressive due to its generally poor prognosis if left unmanaged. Hence, treatment must not await the results of the kidney biopsy; but must be initiated as soon as possible because fibrosis may start very early during the course of the disease. Presence of fibrosis marks irreversible damage.
In some studies, patients already on dialysis were also responsive to therapy and treatment should not be delayed for these patients either.<ref name="pmid8808107">{{cite journal| author=Nachman PH, Hogan SL, Jennette JC, Falk RJ| title=Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. | journal=J Am Soc Nephrol | year= 1996 | volume= 7 | issue= 1 | pages= 33-9 | pmid=8808107 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8808107 }} </ref> Nonetheless, the true response among this specific sub-population and their associated risks and outcomes are poorly understood.<ref name="pmid8808107">{{cite journal| author=Nachman PH, Hogan SL, Jennette JC, Falk RJ| title=Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. | journal=J Am Soc Nephrol | year= 1996 | volume= 7 | issue= 1 | pages= 33-9 | pmid=8808107 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8808107 }} </ref>
===Pharmacologic Therapy===
In 1990, the Glomerular Disease Collaborative Network published its findings after a 24-month follow-up of 70 patients with ANCA and pauci-immune necrotizing and crescentic glomerulonephritis.<ref name="pmid2221646">{{cite journal| author=Falk RJ, Hogan S, Carey TS, Jennette JC| title=Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. | journal=Ann Intern Med | year= 1990 | volume= 113 | issue= 9 | pages= 656-63 | pmid=2221646 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2221646 }} </ref> In the cohort trial, 14 patients were treated with corticosteroids, 30 patients received both corticosteroids and oral cyclophosphamide, 15 patients received both corticosteroids and intravenous cyclophosphamide, and 11 patients received no treatment.<ref name="pmid2221646">{{cite journal| author=Falk RJ, Hogan S, Carey TS, Jennette JC| title=Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. | journal=Ann Intern Med | year= 1990 | volume= 113 | issue= 9 | pages= 656-63 | pmid=2221646 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2221646 }} </ref> The authors concluded that oral corticosteroids with either oral or intravenous cyclophosphamide regimens are equally effective treatment options for patients with ANCA-associated glomerulonephritis for patients with renal-limited disease, glomerulonephritis, and alveolar hemorrhage.<ref name="pmid2221646">{{cite journal| author=Falk RJ, Hogan S, Carey TS, Jennette JC| title=Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. | journal=Ann Intern Med | year= 1990 | volume= 113 | issue= 9 | pages= 656-63 | pmid=2221646 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2221646 }} </ref>
In 1996, Nachman and colleagues outlined a protocol for therapeutic management of patients with microscopic polyangiitis and necrotizing and crescentic glomerulonephritis associated with ANCA. In the trial, 107 patients were enrolled. 25 patients received only corticosteroids, 72 received cyclophosphamide and corticosteroids, and 10 patients did not receive cyclophosphamide or corticosteroids. The authors concluded that 77.3% of those receiving therapy remitted, and 67% of those who were not in remission following the first regimen were in remission after a second course of the same regimen.<ref name="pmid8808107">{{cite journal| author=Nachman PH, Hogan SL, Jennette JC, Falk RJ| title=Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. | journal=J Am Soc Nephrol | year= 1996 | volume= 7 | issue= 1 | pages= 33-9 | pmid=8808107 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8808107 }} </ref>
====Glucocorticoids====
=====Regimen=====
''Follow step 1, then 2, then 3''<br>
'''1. Methylprednisone'''
*''Route'': Intravenous (IV)
*''Dose'': 7 mg/kg/d at a maximum dose of 1 g
*''Duration'': 3 days
'''2. Prednisone'''
*''Route'': Per Os (PO)
*''First Dose'': 1 mg/kg/d at a maximum dose of 80 mg for 3 weeks
*''Second Dose'': 2 mg/kg/d at a maximum dose of 120 mg for 3 months
'''3. Taper'''
*Taper patient off steroids by deceasing 25% of prednisone dose every 4 weeks until patient stops
====Immunosuppressive Therapy====
'''Cyclophosphamide'''
*''Route'': IV or PO
*''Dose'':
**''IV'': 0.5 g/m2, at a maximum dose of 1g/m2. Dose adjusted to a 2-week leukocyte nadir count goal 3000-4000/uL.
**''PO'': 2 mg/kg. Dose adjusted to a 2-week leukocyte nadir count goal 3000-4000/uL
Addition of cyclophosphamides for patients with RPGN is necessary to prevent relapse, which is commonly seen in patients receiving glucocorticoids alone and leads to remission in more than 80% of the cases.<ref name="pmid8808107">{{cite journal| author=Nachman PH, Hogan SL, Jennette JC, Falk RJ| title=Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. | journal=J Am Soc Nephrol | year= 1996 | volume= 7 | issue= 1 | pages= 33-9 | pmid=8808107 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8808107 }} </ref>
The studies excluded patients with granulomatosis with polyangiitis (formerly Wegener granulomatosis). In cases of granulomatosis with polyangiitis (formerly Wegener granulomatosis), oral therapy has been preferred by some experts. IV cyclophosphamide generally have less total dose and thus less toxicity than its oral counterpart.
'''Azathioprine'''<br>
PO azathioprine (AZA) has been recommended by some experts to replace cyclophosphamide after an initial 3-month induction period of cyclophosphamide.
*''Route'': PO
*''Dose'': 2 mg/kg
*''Duration'': 6-12 months
'''Methotrexate'''<br>
Methotrexate (MTX) has been used in mild forms of granulomatosis with polyangiitis (formerly Wegener granulomatosis) as a replacement for cyclophosphamide.<ref name="pmid17873756">{{cite journal| author=Villa-Forte A, Clark TM, Gomes M, Carey J, Mascha E, Karafa MT et al.| title=Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience. | journal=Medicine (Baltimore) | year= 2007 | volume= 86 | issue= 5 | pages= 269-77 | pmid=17873756 | doi=10.1097/MD.0b013e3181568ec0 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17873756 }} </ref> In more severe forms, it has been used following short-term induction therapy with cyclophosphamide.<ref name="pmid17873756">{{cite journal| author=Villa-Forte A, Clark TM, Gomes M, Carey J, Mascha E, Karafa MT et al.| title=Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience. | journal=Medicine (Baltimore) | year= 2007 | volume= 86 | issue= 5 | pages= 269-77 | pmid=17873756 | doi=10.1097/MD.0b013e3181568ec0 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17873756 }} </ref> Villa-Forte and colleagues enrolled 82 patients in 2007; 70% of those had severe disease on admission and required cyclophosphamide for remission induction. Severity was based on clinical and histopathological findings: pulmonary hemorrhage, neurological abnormalities, need for dialysis, serum creatinine > 2 mg/dL, and RPGN. 72% of patients were in remission after 1 year, and 91% reached remission at any duration. Relapse rates were as high as 66% within 2 years, most of which responded to reinitiation of therapy.
''Induction of Remission for Severe Cases:''
*Cyclophosphamide
**''Route'': PO
**''Dose'': 2 mg/kg adjusted for renal function and WBC count
*Prednisone
**''Route'': PO
**''Dose'': 1 mg/kg
''Initial Treatment:''
*Methotrexate (MTX)
**''Route'': PO
**''Dose'': 15 mg/wk increased over 4-8 weeks to 25 mg/wk if tolerated and if necessary
**''Duration'': At least 2 years
*Prednisone
**''Route'': PO
**''Dose'': 1 mg/kg/d to gradually decrease as long as no documented disease recurrence
'''Rituximab'''<br>
The RITUXVAS (Randomized trial of Rituximab vs. Cyclophosphamide in ANCA-Associated Vasculitis) and RAVE (Rituximab in ANCA-Associated Vasculitis Trial) trials<ref name="pmid22095945">{{cite journal| author=Berden AE, Jones RB, Erasmus DD, Walsh M, Noël LH, Ferrario F et al.| title=Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy. | journal=J Am Soc Nephrol | year= 2012 | volume= 23 | issue= 2 | pages= 313-21 | pmid=22095945 | doi=10.1681/ASN.2011040330 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22095945 }} </ref> showed in 2012 that anti-B therapy by rituximab, a chimeric anti-human CD20 monoclonal antibody, may improve renal survival in patients with vasculitis and positive ANCA and had renal impairment, including patients with granulomatosis with polyangiitis (formerly Wegener granulomatosis).<ref name="pmid22095945">{{cite journal| author=Berden AE, Jones RB, Erasmus DD, Walsh M, Noël LH, Ferrario F et al.| title=Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy. | journal=J Am Soc Nephrol | year= 2012 | volume= 23 | issue= 2 | pages= 313-21 | pmid=22095945 | doi=10.1681/ASN.2011040330 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22095945 }} </ref> The findings were based on earlier reports of improved outcome using rituximab.
''Regimen:''
Rituximab:
*''Route'': IV
*''Dose'': 375 mg/m2
*''Duration'': Once weekly 4 consecutive weeks
Cyclophosphamide
*''Route'': IV
*''Dose'': 15 mg/kg
*''Duration'': Co-administed with 1st and 3rd rituximab doses
Methylprednisolone
*''Route'': IV and PO
*''Dose'': 1g IV then followed by daily low-dose oral corticosteroids for maintenance
'''Other'''<br>
Some medications have never been studied. However, they have been shown to be effective based on findings in case reports. These medications include:
*IV immunoglobulins (Igs)
*Antithymocyte antibody
*Monoclonal antibodies to CD4
*Monoclonal antibodies to CD25
===Plasma Exchange===
Indications of plasma exchange:
*Removal of circulating auto-antibodies in patients with anti-GBM antibody disease
*Patients with high risk of renal failure
*Patients with serum creatinine > 2.3 mg/dL<ref name="pmid9241619">{{cite journal| author=Levy JB, Pusey CD| title=Still a role for plasma exchange in rapidly progressive glomerulonephritis? | journal=J Nephrol | year= 1997 | volume= 10 | issue= 1 | pages= 7-13 | pmid=9241619 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9241619 }} </ref>
*Patients who do not respond to pharmacologic therapy
*Patients diagnosed with pauci-immune crescenteric glomerulonephriits with ESRD and need dialysis<ref name="pmid9241619">{{cite journal| author=Levy JB, Pusey CD| title=Still a role for plasma exchange in rapidly progressive glomerulonephritis? | journal=J Nephrol | year= 1997 | volume= 10 | issue= 1 | pages= 7-13 | pmid=9241619 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9241619 }} </ref>
The true value of plasma exchange has been demonstrated by a few small trials in secondary analysis.<ref name="pmid9744974">{{cite journal| author=Hricik DE, Chung-Park M, Sedor JR| title=Glomerulonephritis. | journal=N Engl J Med | year= 1998 | volume= 339 | issue= 13 | pages= 888-99 | pmid=9744974 | doi=10.1056/NEJM199809243391306 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9744974 }} </ref> The real indications and benefit to risk ratio of plasma exchange are yet to be elucidated.


==References==
==References==

Revision as of 03:11, 22 May 2018

Rapidly progressive glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Rapidly progressive glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray Findings

CT-scan Findings

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Rapidly progressive glomerulonephritis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rapidly progressive glomerulonephritis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Rapidly progressive glomerulonephritis medical therapy

CDC on Rapidly progressive glomerulonephritis medical therapy

Rapidly progressive glomerulonephritis medical therapy in the news

Blogs on Rapidly progressive glomerulonephritis medical therapy

Directions to Hospitals Treating Rapidly progressive glomerulonephritis

Risk calculators and risk factors for Rapidly progressive glomerulonephritis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical therapy

Treatment of RPGN must be very aggressive due to its generally poor prognosis if left unmanaged. Hence, treatment must not await the results of the kidney biopsy; but must be initiated as soon as possible because fibrosis may start very early during the course of the disease. Presence of fibrosis marks irreversible damage.

In some studies, patients already on dialysis were also responsive to therapy and treatment should not be delayed for these patients either.[1] Nonetheless, the true response among this specific sub-population and their associated risks and outcomes are poorly understood.[1]

Pharmacologic Therapy

In 1990, the Glomerular Disease Collaborative Network published its findings after a 24-month follow-up of 70 patients with ANCA and pauci-immune necrotizing and crescentic glomerulonephritis.[2] In the cohort trial, 14 patients were treated with corticosteroids, 30 patients received both corticosteroids and oral cyclophosphamide, 15 patients received both corticosteroids and intravenous cyclophosphamide, and 11 patients received no treatment.[2] The authors concluded that oral corticosteroids with either oral or intravenous cyclophosphamide regimens are equally effective treatment options for patients with ANCA-associated glomerulonephritis for patients with renal-limited disease, glomerulonephritis, and alveolar hemorrhage.[2]

In 1996, Nachman and colleagues outlined a protocol for therapeutic management of patients with microscopic polyangiitis and necrotizing and crescentic glomerulonephritis associated with ANCA. In the trial, 107 patients were enrolled. 25 patients received only corticosteroids, 72 received cyclophosphamide and corticosteroids, and 10 patients did not receive cyclophosphamide or corticosteroids. The authors concluded that 77.3% of those receiving therapy remitted, and 67% of those who were not in remission following the first regimen were in remission after a second course of the same regimen.[1]

Glucocorticoids

Regimen

Follow step 1, then 2, then 3
1. Methylprednisone

  • Route: Intravenous (IV)
  • Dose: 7 mg/kg/d at a maximum dose of 1 g
  • Duration: 3 days

2. Prednisone

  • Route: Per Os (PO)
  • First Dose: 1 mg/kg/d at a maximum dose of 80 mg for 3 weeks
  • Second Dose: 2 mg/kg/d at a maximum dose of 120 mg for 3 months

3. Taper

  • Taper patient off steroids by deceasing 25% of prednisone dose every 4 weeks until patient stops

Immunosuppressive Therapy

Cyclophosphamide

  • Route: IV or PO
  • Dose:
    • IV: 0.5 g/m2, at a maximum dose of 1g/m2. Dose adjusted to a 2-week leukocyte nadir count goal 3000-4000/uL.
    • PO: 2 mg/kg. Dose adjusted to a 2-week leukocyte nadir count goal 3000-4000/uL

Addition of cyclophosphamides for patients with RPGN is necessary to prevent relapse, which is commonly seen in patients receiving glucocorticoids alone and leads to remission in more than 80% of the cases.[1] The studies excluded patients with granulomatosis with polyangiitis (formerly Wegener granulomatosis). In cases of granulomatosis with polyangiitis (formerly Wegener granulomatosis), oral therapy has been preferred by some experts. IV cyclophosphamide generally have less total dose and thus less toxicity than its oral counterpart.

Azathioprine
PO azathioprine (AZA) has been recommended by some experts to replace cyclophosphamide after an initial 3-month induction period of cyclophosphamide.

  • Route: PO
  • Dose: 2 mg/kg
  • Duration: 6-12 months

Methotrexate
Methotrexate (MTX) has been used in mild forms of granulomatosis with polyangiitis (formerly Wegener granulomatosis) as a replacement for cyclophosphamide.[3] In more severe forms, it has been used following short-term induction therapy with cyclophosphamide.[3] Villa-Forte and colleagues enrolled 82 patients in 2007; 70% of those had severe disease on admission and required cyclophosphamide for remission induction. Severity was based on clinical and histopathological findings: pulmonary hemorrhage, neurological abnormalities, need for dialysis, serum creatinine > 2 mg/dL, and RPGN. 72% of patients were in remission after 1 year, and 91% reached remission at any duration. Relapse rates were as high as 66% within 2 years, most of which responded to reinitiation of therapy.

Induction of Remission for Severe Cases:

  • Cyclophosphamide
    • Route: PO
    • Dose: 2 mg/kg adjusted for renal function and WBC count
  • Prednisone
    • Route: PO
    • Dose: 1 mg/kg

Initial Treatment:

  • Methotrexate (MTX)
    • Route: PO
    • Dose: 15 mg/wk increased over 4-8 weeks to 25 mg/wk if tolerated and if necessary
    • Duration: At least 2 years
  • Prednisone
    • Route: PO
    • Dose: 1 mg/kg/d to gradually decrease as long as no documented disease recurrence

Rituximab
The RITUXVAS (Randomized trial of Rituximab vs. Cyclophosphamide in ANCA-Associated Vasculitis) and RAVE (Rituximab in ANCA-Associated Vasculitis Trial) trials[4] showed in 2012 that anti-B therapy by rituximab, a chimeric anti-human CD20 monoclonal antibody, may improve renal survival in patients with vasculitis and positive ANCA and had renal impairment, including patients with granulomatosis with polyangiitis (formerly Wegener granulomatosis).[4] The findings were based on earlier reports of improved outcome using rituximab. Regimen: Rituximab:

  • Route: IV
  • Dose: 375 mg/m2
  • Duration: Once weekly 4 consecutive weeks

Cyclophosphamide

  • Route: IV
  • Dose: 15 mg/kg
  • Duration: Co-administed with 1st and 3rd rituximab doses

Methylprednisolone

  • Route: IV and PO
  • Dose: 1g IV then followed by daily low-dose oral corticosteroids for maintenance

Other
Some medications have never been studied. However, they have been shown to be effective based on findings in case reports. These medications include:

  • IV immunoglobulins (Igs)
  • Antithymocyte antibody
  • Monoclonal antibodies to CD4
  • Monoclonal antibodies to CD25

Plasma Exchange

Indications of plasma exchange:

  • Removal of circulating auto-antibodies in patients with anti-GBM antibody disease
  • Patients with high risk of renal failure
  • Patients with serum creatinine > 2.3 mg/dL[5]
  • Patients who do not respond to pharmacologic therapy
  • Patients diagnosed with pauci-immune crescenteric glomerulonephriits with ESRD and need dialysis[5]

The true value of plasma exchange has been demonstrated by a few small trials in secondary analysis.[6] The real indications and benefit to risk ratio of plasma exchange are yet to be elucidated.

References

  1. 1.0 1.1 1.2 1.3 Nachman PH, Hogan SL, Jennette JC, Falk RJ (1996). "Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis". J Am Soc Nephrol. 7 (1): 33–9. PMID 8808107.
  2. 2.0 2.1 2.2 Falk RJ, Hogan S, Carey TS, Jennette JC (1990). "Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network". Ann Intern Med. 113 (9): 656–63. PMID 2221646.
  3. 3.0 3.1 Villa-Forte A, Clark TM, Gomes M, Carey J, Mascha E, Karafa MT; et al. (2007). "Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience". Medicine (Baltimore). 86 (5): 269–77. doi:10.1097/MD.0b013e3181568ec0. PMID 17873756.
  4. 4.0 4.1 Berden AE, Jones RB, Erasmus DD, Walsh M, Noël LH, Ferrario F; et al. (2012). "Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy". J Am Soc Nephrol. 23 (2): 313–21. doi:10.1681/ASN.2011040330. PMID 22095945.
  5. 5.0 5.1 Levy JB, Pusey CD (1997). "Still a role for plasma exchange in rapidly progressive glomerulonephritis?". J Nephrol. 10 (1): 7–13. PMID 9241619.
  6. Hricik DE, Chung-Park M, Sedor JR (1998). "Glomerulonephritis". N Engl J Med. 339 (13): 888–99. doi:10.1056/NEJM199809243391306. PMID 9744974.

Template:WH Template:WS